APA (7th ed.) Citation

TA, N., NK, M., M, M., J, A., AR, B., Y, J., . . . J, D. (2024). Clinical Reasoning: Assessing New Neurologic Deficits in Patients With Hematologic Malignancy on Bruton Tyrosine Kinase Inhibitor Therapy. Neurology, 103(9), e209929. https://doi.org/10.1212/WNL.0000000000209929

Chicago Style (17th ed.) Citation

TA, Nelson, et al. "Clinical Reasoning: Assessing New Neurologic Deficits in Patients With Hematologic Malignancy on Bruton Tyrosine Kinase Inhibitor Therapy." Neurology 103, no. 9 (2024): e209929. https://doi.org/10.1212/WNL.0000000000209929.

MLA (9th ed.) Citation

TA, Nelson, et al. "Clinical Reasoning: Assessing New Neurologic Deficits in Patients With Hematologic Malignancy on Bruton Tyrosine Kinase Inhibitor Therapy." Neurology, vol. 103, no. 9, 2024, p. e209929, https://doi.org/10.1212/WNL.0000000000209929.